ssa retatrutide Promises Big Weight Loss, but Safety Remains a Question 🔥 Synergistic Fat Loss Stack

In metabolic and body weight research it is studied as a next generation successor to single agonists such as semaglutide and dual agonists such as tirzepatide, because hitting three pathways at once is a distinct mechanism from those earlier compounds

Andreas Nygaard M, Gitte H, Sarah Juel P, et al

Also the confusion between a true micro dose (not for weight) and a low dose and why people feel more comfortable with calling it microdosing belies more about weight health bias that we need to unpack - the shame about using this tool is driving a lot of suboptimal outcomes thx for shining a light Joanna Strober Agreed

Ongoing trials by Novo Nordisk aim to explore the link between semaglutide use and diabetic retinopathy, with results expected by 2027